GB0600488D0 - Immunoglobulins - Google Patents
ImmunoglobulinsInfo
- Publication number
- GB0600488D0 GB0600488D0 GBGB0600488.1A GB0600488A GB0600488D0 GB 0600488 D0 GB0600488 D0 GB 0600488D0 GB 0600488 A GB0600488 A GB 0600488A GB 0600488 D0 GB0600488 D0 GB 0600488D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- immunoglobulins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
PE2007000018A PE20081185A1 (en) | 2006-01-11 | 2007-01-09 | ANTIBODIES THAT BIND HUMAN INTERLEUKIN 13 (IL-13) AND COMPOSITIONS THAT UNDERSTAND IT |
TW096100833A TW200736274A (en) | 2006-01-11 | 2007-01-09 | Immunoglobulins |
ARP070100082A AR058955A1 (en) | 2006-01-11 | 2007-01-09 | IMMUNGLOBULINS THAT JOIN INTERLEUQUINA 13 |
KR1020087019555A KR20080113201A (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
EP07703766A EP1976881A2 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
AU2007204372A AU2007204372A1 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human IL-13 antibodies |
JP2008549873A JP2009523154A (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanized anti-human IL-13 antibodies |
CA002635972A CA2635972A1 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
BRPI0706481-0A BRPI0706481A2 (en) | 2006-01-11 | 2007-01-10 | antibody or antigen-binding fragment thereof, humanized antibody, antigen-binding fragment, transformed or transfected recombinant host cell, methods of producing an antibody, for treating a human patient afflicted with a disease, to prevent acute asthmatic attacks in a human patient , and to reduce the frequency and / or mitigate the effects of acute asthmatic attacks on a human patient, pharmaceutical composition, kit of parts, and use of an antibody or antigen-binding fragment thereof. |
PCT/EP2007/050219 WO2007080174A2 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
EA200801520A EA200801520A1 (en) | 2006-01-11 | 2007-01-10 | CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) |
CNA2007800022973A CN101370829A (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human IL-13 antibodies |
IL192207A IL192207A0 (en) | 2006-01-11 | 2008-06-16 | Chimeric and humanised anti-human il -13 antibodies |
NO20082767A NO20082767L (en) | 2006-01-11 | 2008-06-16 | Chimeric and humanized anti-human IL-13 antibodies |
ZA200805526A ZA200805526B (en) | 2006-01-11 | 2008-06-24 | Chimeric and humanised anti-human IL-13 antibodies |
MA31108A MA30156B1 (en) | 2006-01-11 | 2008-07-11 | IMMUNOGLOBULIN |
CR10161A CR10161A (en) | 2006-01-11 | 2008-07-17 | IMMUNOGLOBULINS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0600488D0 true GB0600488D0 (en) | 2006-02-22 |
Family
ID=35997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0600488.1A Ceased GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1976881A2 (en) |
JP (1) | JP2009523154A (en) |
KR (1) | KR20080113201A (en) |
CN (1) | CN101370829A (en) |
AR (1) | AR058955A1 (en) |
AU (1) | AU2007204372A1 (en) |
BR (1) | BRPI0706481A2 (en) |
CA (1) | CA2635972A1 (en) |
CR (1) | CR10161A (en) |
EA (1) | EA200801520A1 (en) |
GB (1) | GB0600488D0 (en) |
IL (1) | IL192207A0 (en) |
MA (1) | MA30156B1 (en) |
NO (1) | NO20082767L (en) |
PE (1) | PE20081185A1 (en) |
TW (1) | TW200736274A (en) |
WO (1) | WO2007080174A2 (en) |
ZA (1) | ZA200805526B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR058104A1 (en) | 2005-10-21 | 2008-01-23 | Novartis Ag | ORGANIC COMPOUNDS |
JP5420399B2 (en) | 2006-05-25 | 2014-02-19 | グラクソ グループ リミテッド | Modified humanized anti-interleukin-18 antibody |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
KR20110092328A (en) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ligands that bind il-13 |
KR101579771B1 (en) | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | IL-17 binding proteins |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
JP5919188B2 (en) | 2009-05-28 | 2016-05-18 | グラクソ グループ リミテッドGlaxo Group Limited | IL-13 binding protein |
HUE053489T2 (en) * | 2009-10-20 | 2021-06-28 | Abbvie Inc | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
DK2627673T3 (en) * | 2010-10-15 | 2017-11-06 | Medimmune Ltd | THERAPY TO IMPROVE LUNGE FUNCTION |
KR101615420B1 (en) | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Diagnosis and treatments relating to th2 inhibition |
EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
AR098155A1 (en) | 2013-10-23 | 2016-05-04 | Genentech Inc | METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS |
AU2015218631A1 (en) | 2014-02-21 | 2016-08-11 | Genentech, Inc. | Anti-IL-13/IL-17 bispecific antibodies and uses thereof |
CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
KR20170127011A (en) | 2015-03-16 | 2017-11-20 | 제넨테크, 인크. | Methods for detecting and quantifying IL-13 and for diagnosing and treating TH2-related diseases |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
JPWO2018135653A1 (en) * | 2017-01-23 | 2020-01-09 | 学校法人 東洋大学 | Anti-EPHA2 antibody and immunological detection of EPHA2 using the same |
CN109776677B (en) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | Humanized anti-IL-13 antibody and preparation method and application thereof |
CN107909501B (en) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | Smell and behavior association method, smell social method and device |
CA3226165A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
EP3938405A4 (en) * | 2019-03-20 | 2022-12-28 | Javelin Oncology, Inc. | Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003259374A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Vaccine comprising il-13 and an adjuvant |
WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
ATE552850T1 (en) * | 2003-12-23 | 2012-04-15 | Genentech Inc | NEW ANTI-IL 13 ANTIBODIES AND USES THEREOF |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 AR ARP070100082A patent/AR058955A1/en unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/en not_active Application Discontinuation
- 2007-01-09 TW TW096100833A patent/TW200736274A/en unknown
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/en not_active IP Right Cessation
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en active Application Filing
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/en active Pending
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/en active Pending
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
- 2007-01-10 EA EA200801520A patent/EA200801520A1/en unknown
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/en not_active Application Discontinuation
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/en not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/en unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/en unknown
- 2008-07-17 CR CR10161A patent/CR10161A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20082767L (en) | 2008-10-06 |
CA2635972A1 (en) | 2007-07-19 |
TW200736274A (en) | 2007-10-01 |
CN101370829A (en) | 2009-02-18 |
WO2007080174A3 (en) | 2007-12-06 |
KR20080113201A (en) | 2008-12-29 |
MA30156B1 (en) | 2009-01-02 |
CR10161A (en) | 2008-11-26 |
JP2009523154A (en) | 2009-06-18 |
BRPI0706481A2 (en) | 2011-03-29 |
EP1976881A2 (en) | 2008-10-08 |
AU2007204372A1 (en) | 2007-07-19 |
AR058955A1 (en) | 2008-03-05 |
EA200801520A1 (en) | 2009-02-27 |
WO2007080174A2 (en) | 2007-07-19 |
PE20081185A1 (en) | 2008-10-07 |
IL192207A0 (en) | 2008-12-29 |
ZA200805526B (en) | 2009-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0600488D0 (en) | Immunoglobulins | |
DE602007002700D1 (en) | Interventionsfreies frac-system | |
EP2033216A4 (en) | Electroadhesion | |
DE602007008085D1 (en) | Dihydropyrazolopyrimidinonderivate | |
DE602007014031D1 (en) | Luftreifensatz | |
DE602007002070D1 (en) | 2-pyrazincarboxamidderivate | |
DE602007003855D1 (en) | Isothermer reaktor | |
EP1983992A4 (en) | 2-imino-benzimidazoles | |
DE602007001601D1 (en) | Glasuntersuchung | |
HK1109502A1 (en) | Battary can | |
DE602007006989D1 (en) | Spiropiperidinderivate | |
GB0624102D0 (en) | Boot-jacks | |
AP2008004724A0 (en) | Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane | |
DE602007011622D1 (en) | Penem-prodrugs | |
EP2024567A4 (en) | Earthen-wallpaper | |
EP2007388A4 (en) | Opiopathies | |
DK1989111T3 (en) | Satellitluftbremseapparat | |
GB0513766D0 (en) | Immunoglobulins | |
EP1974618A4 (en) | Innerwear | |
DE502007001126D1 (en) | Eiten | |
GB0609373D0 (en) | Macrolones | |
GB0602258D0 (en) | Privyphone | |
GB0610438D0 (en) | Immunoglobulins | |
GB0611046D0 (en) | Immunoglobulins | |
AU4914P (en) | CalflatGL Calothamnus quadrifidus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |